Centre flags data gap, regulatory hurdles in curbing hospital mark-ups

A hospital mark-up is the difference between a hospital’s purchase price for a medicine or consumable and the amount billed to the patient. It shows how much more the hospital charges than its acquisition cost. This matters because the Union government told the Supreme Court that some margins may be extremely high.

For example, if a hospital buys a consumable at a low price but bills the patient at a much higher amount, the gap is the mark-up. The printed MRP is different: it is the maximum retail price shown on the product. The article notes that there is no general legal requirement for hospitals to charge below that printed price.

The government says it needs purchase and billing data to measure these gaps properly. It is also considering how insurance delays, government-scheme reimbursements, and package billing affect hospital finances. Those factors could influence any future decision on wider controls.

The Union government told the Supreme Court that margins on hospital consumables can range from 100% to 1,000% or more. These figures indicate a potentially very large difference between what hospitals pay and what patients are billed. The issue matters because consumables are used during treatment and can substantially increase hospital expenses.

A 100% margin represents an amount equal to the purchase cost added on top of it. A 1,000% margin is far larger, representing ten times the purchase cost as the margin itself. The article does not provide a specific product, hospital, or patient bill as an example.

The government has not yet established margins across all hospital supplies. Officials say they need purchase-price and billing data before deciding whether broader controls are justified. They also point to package rates, delayed reimbursements, and possible regulatory limits on hospital billing.

The Centre wants evidence before extending price controls to hospital supplies. Officials say current data does not show margins across the full range of medicines and consumables used by hospitals. Without that information, the government cannot determine how widespread high mark-ups are or whether intervention is needed.

The key mechanism is a comparison between two figures: what a hospital pays to buy a product and what it charges the patient. Officials also need to consider how hospitals bill, because many use package rates instead of detailed, itemised bills. That can make individual product charges difficult to identify.

The government says any wider controls would require analysis and consultation. Officials also mention delayed payments from insurers and government health schemes as financial pressures on hospitals. These issues may affect how possible controls are designed, although no broader intervention has been announced.

India already regulates several medicine prices, but these controls do not automatically cover every hospital supply. The Centre fixes ceiling prices for scheduled medicines. For non-scheduled drugs, annual price increases are limited to 10%. These rules aim to restrain medicine-price growth.

The government has also decided to cap trade margins on certain anti-cancer medicines at 30% of MRP. The National Pharmaceutical Pricing Authority, or NPPA, is the Centre’s main agency for drug-price regulation. These measures focus on medicines rather than every component of a hospital bill.

Officials say applying similar controls to more medicines and hospital consumables would need further analysis and consultation. The article also notes that hospitals often charge package rates. That makes it harder to separate the price of each medicine or consumable from other treatment charges.

Regulating a medicine price is more straightforward when the product and its printed price can be identified. The Centre regulates drug prices through the National Pharmaceutical Pricing Authority. Hospital billing is broader because one bill may combine medicines, consumables, treatment services, and other fees.

The article says hospitals often charge package rates rather than giving detailed itemised bills. That makes it difficult to compare the purchase price of one consumable with the amount charged to a patient. Hospitals may also face delayed reimbursements from insurers and government health schemes, which officials say should be considered.

There is also a division of responsibility. Health is a state subject, and hospitals are governed by the Clinical Establishments Act or other state laws. The Centre’s role is largely drug-price regulation. Controlling every hospital-bill component could therefore create legal and practical difficulties.

Capping consumable prices could reduce one source of hospital revenue, but it might not reduce the total bill. A health ministry official warned that hospitals seeking to protect profits could shift charges elsewhere. This matters because regulating one line item may not control the final cost of treatment.

The article gives a specific example: hospitals could raise surgeons’ charges if the government restricted what they could charge for consumables. Hospitals may also use package rates, making it difficult to see exactly where a higher or lower charge appears. Patients could therefore face a similar overall bill, even if consumable prices are limited.

This is one reason officials are cautious about wider intervention. They say the government first needs better data and must consider delayed reimbursements from insurers and government schemes. The article does not report that any such cap has been introduced for hospital consumables.

Healthcare responsibilities are divided between the Union and state governments. The article identifies health as a state subject. State governments make laws governing hospitals, including the Clinical Establishments Act or other applicable laws. This gives states an important role in regulating hospital operations and billing.

The Union government’s role is described as largely confined to drug-price regulation through the National Pharmaceutical Pricing Authority. It sets ceiling prices for scheduled medicines, limits annual increases for non-scheduled drugs, and has capped trade margins on certain anti-cancer medicines. These powers concern medicines rather than complete hospital bills.

This division creates a practical challenge for broader controls. The Centre may regulate medicine prices, but regulating every hospital-bill component could involve state laws and different billing systems. Officials also say package rates and delayed reimbursements complicate any national approach to hospital charges.